BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 20875089)

  • 1. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy.
    Walz J; Joniau S; Chun FK; Isbarn H; Jeldres C; Yossepowitch O; Chao-Yu H; Klein EA; Scardino PT; Reuther A; Poppel HV; Graefen M; Huland H; Karakiewicz PI
    BJU Int; 2011 Mar; 107(5):765-770. PubMed ID: 20875089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer.
    Ploussard G; Salomon L; Allory Y; Terry S; Vordos D; Hoznek A; Abbou CC; Vacherot F; de la Taille A
    BJU Int; 2010 Jul; 106(1):86-90. PubMed ID: 19930177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?
    Boorjian SA; Bianco FJ; Scardino PT; Eastham JA
    BJU Int; 2005 Oct; 96(6):773-6. PubMed ID: 16153197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?
    Klaassen Z; Singh AA; Howard LE; Feng Z; Trock B; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Kane CJ; Partin A; Han M; Freedland SJ
    Cancer; 2015 May; 121(9):1414-21. PubMed ID: 25492369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of a positive surgical margin in pathologically organ-confined prostate cancer.
    Ahyai SA; Zacharias M; Isbarn H; Steuber T; Eichelberg C; Köllermann J; Fisch M; Karakiewicz PI; Huland H; Graefen M; Chun FK
    BJU Int; 2010 Aug; 106(4):478-83. PubMed ID: 20128781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of statin use on clinicopathological characteristics of localized prostate cancer and outcomes obtained after radical prostatectomy: a single center study.
    Cattarino S; Seisen T; Drouin SJ; Renard-Penna R; Leon P; Comperat E; Mozer P; Cussenot O; Rouprêt M
    Can J Urol; 2015 Apr; 22(2):7703-8. PubMed ID: 25891333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.
    Isbarn H; Wanner M; Salomon G; Steuber T; Schlomm T; Köllermann J; Sauter G; Haese A; Heinzer H; Huland H; Graefen M
    BJU Int; 2010 Jul; 106(1):37-43. PubMed ID: 20002667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
    Narita S; Mitsuzuka K; Tsuchiya N; Koie T; Kawamura S; Ohyama C; Tochigi T; Yamaguchi T; Arai Y; Habuchi T;
    Int J Urol; 2015 Nov; 22(11):1029-35. PubMed ID: 26290306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.
    Pierorazio PM; Ross AE; Lin BM; Epstein JI; Han M; Walsh PC; Partin AW; Pavlovich CP; Schaeffer EM
    BJU Int; 2012 Oct; 110(8):1122-8. PubMed ID: 22373045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laparoscopic radical prostatectomy monotherapy, a more aggressive yet less invasive option, is oncologically effective in selected men with high-risk prostate cancer having only one D'Amico risk factor: experience from an Asian tertiary referral center.
    Tai HC; Lai MK; Huang CY; Wang SM; Huang KH; Chen CH; Chung SD; Chueh SC; Yu HJ; Pu YS
    J Endourol; 2014 Feb; 28(2):165-71. PubMed ID: 23987245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of greater short-term PSA recurrence with laparoscopic as compared to retropubic radical prostatectomy for Japanese clinically localized prostate carcinomas.
    Akita H; Okamura T; Ando R; Nagata D; Naruyama H; Yamada Y; Naiki T; Yasui T; Tozawa K; Kohri K
    Asian Pac J Cancer Prev; 2011; 12(11):2959-61. PubMed ID: 22393971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short (≤ 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy.
    Shikanov S; Marchetti P; Desai V; Razmaria A; Antic T; Al-Ahmadie H; Zagaja G; Eggener S; Brendler C; Shalhav A
    BJU Int; 2013 Apr; 111(4):559-63. PubMed ID: 22759270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site of positive surgical margins influences biochemical recurrence after radical prostatectomy.
    Godoy G; Tareen BU; Lepor H
    BJU Int; 2009 Dec; 104(11):1610-4. PubMed ID: 19549257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series.
    Gandaglia G; Ploussard G; Isbarn H; Suardi N; De Visschere PJ; Futterer JJ; Ghadjar P; Massard C; Ost P; Sooriakumaran P; Surcel CI; van der Bergh RC; Montorsi F; Ficarra V; Giannarini G; Briganti A;
    Urol Oncol; 2015 Apr; 33(4):164.e1-9. PubMed ID: 25620154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of the Biochemical Recurrence risk between Radical Prostatectomy and Brachytherapy in the treatment of low- and intermediate-risk prostate cancer].
    Martínez PF; Belisle DF; Cristallo C; Tobía I; Damia O; Villamil W; Giudice CR
    Arch Esp Urol; 2015 Oct; 68(8):655-60. PubMed ID: 26437328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram.
    Abdollah F; Klett DE; Sood A; Sammon JD; Pucheril D; Dalela D; Diaz M; Peabody JO; Trinh QD; Menon M
    BJU Int; 2015 Nov; 116(5):703-12. PubMed ID: 25413443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors for short-term biochemical recurrence-free survival after robot-assisted laparoscopic radical prostatectomy in high-risk prostate cancer patients.
    Kanehira M; Takata R; Ishii S; Ito A; Ikarashi D; Matsuura T; Kato Y; Obara W
    Int J Clin Oncol; 2019 Sep; 24(9):1099-1104. PubMed ID: 30972506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.